Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.
[[thumbnail_alt_text]]
FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.
[[thumbnail_alt_text]]
Obstacles to cancer screenings for low-income patients can include lack of transportation and an inability to take time off of work.
 
[[thumbnail_alt_text]]
Narsoplimab is an investigational, fully human IgG4 monoclonal antibody was designed to bind to mannan-binding lectin-associated serine protease-2 
[[thumbnail_alt_text]]
According to Senhwa Biosciences, the study’s findings indicate a clinically meaningful improvement in progression-free survival (PFS) (P<0.05). 
[[thumbnail_alt_text]]
A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.
[[thumbnail_alt_text]]
The FDA approved Enhertu in January 2020 for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
 
[[thumbnail_alt_text]]
Experts in the field of chronic lymphocytic management [CLL] discuss important disease-related factors to take into consideration when determining a patient’s therapy regimen.
[[thumbnail_alt_text]]
A survey found that the majority of oncologists did not feel like they could perform their duties as well as they could prior to the COVID-19 pandemic.
[[thumbnail_alt_text]]
Novel program found cost effective and safe for patients with cancer managing the adverse effects of treatment. 
 
[[thumbnail_alt_text]]
Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.
 
[[thumbnail_alt_text]]
Katie Culos, PharmD, BCOP and Daniel Wojenski, PharmD, BCPS, BCOP discuss the NCCN (National Comprehensive Cancer Center)-recommended front-line treatment options for patients with newly diagnosed CLL ([chronic lymphocytic leukemia)].